CIZ1B Test Approved For Clinical Use in USA

AI SummaryClose X

Cizzle Biotechnology Holdings Plc has achieved a significant milestone with the CLIA accreditation of its CIZ1B biomarker test for early lung cancer detection in the USA, enabling its clinical use through OmniHealth Diagnostics. This accreditation signifies that the test meets stringent US federal standards for accuracy, reliability, and patient safety, paving the way for commercial launch, revenue generation, and potential Medicare and Medicaid reimbursements. The company is now exploring new commercial relationships in the UK, Europe, and Asia, aiming to deliver shareholder value through licensing royalties and equity participation.

Disclaimer*

UK 100

Latest directors dealings